Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Scientists developed a new nanostructure that triples CRISPR’s ability to enter cells, unlocking even more power to treat ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, analyst Mitchell Kapoor from H.C. Wainwright reiterated a “Buy” rating on ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing ...

"Eugenics seeks to improve by eliminating the characteristics considered at a particular time and place to be disadvantages and to maximize those considered normal." When you purchase through links on ...

We expect investors to focus on the sales performance of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other pipeline updates when the company reports its second-quarter 2025 results.

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

That’s why a team from UC San Diego in La Jolla set out with Yale University researchers to develop a new system for gene ...